The Effectiveness and Safety of Tenofovir Alafenamide in the Treatment of Chronic Hepatitis B Patients With Mildly Elevated Alanine Aminotransferase and Significant Liver Injury.

Inclusion Criteria: * Age more than 20 years * Presence of HBsAg positivity for more than 6 months that indicated chronic HBV infection; * HBV viral load more than 20000 IU/mL in HBeAg positive or more than 2000 IU/mL in HBeAg Negative CHB patients; * Presence of liver injury which was defined as histology activity index (HAI) \>3 by Knodell necroinflammantion scoring system or liver fibrosis stage 2 or stage 3 by Metavir scoring system; Liver histology available for evaluation 6 months before starting screening is also acceptable. This criteria is limited to subjects enrolling TAF treatment group. * ALT level between 1-2 folds of ULN for at least one occasion in recent 1 year before screening; * Treatment naïve; Exclusion Criteria: * Other etiology of chronic hepatitis; Those patients with spontaneous clearance of HCV defined as presence of anti-HCV antibody but undetectable of HCV RNA at least 3 months before enrollment and without history of anti-viral treatment could be included. * Severe comorbid disorders; * Uncontrolled diabetes mellitus (HBA1c \> 8.5%); * Current evidence or suspicious of malignancy; * Diagnosis of liver cirrhosis; * eGFR \< or = 30 ml/min/1.73m2. * Any one of following hematology or biochemical or clinical abnormalities: Albumin \<3.5g/dL, Total Bilirubin \>2.5mg/dL, prothrombin time prolongation \>4 sec or INR \>1.7, platelet count \<100 x 103 uL, and history or presence of ascites or hepatic encephalopathy. * Child-bearing age women without th…